Peptide Atlas · Peptide

IGF-1 (Mecasermin / recombinant human IGF-1)

Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone insensitivity), approved in the United States in 2005 and in Europe in 2007.

established

provisional
2 citations
0 discussions
0 followers
IGF-I
Increlex
Mecasermin
Somatomedin C
rhIGF-1

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

No trial registration is cited for it. A registered trial cites as an NCT number and resolves through ClinicalTrials.gov.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.